Action SDZ SANDOZ GROUP AG
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Sandoz Group AG

Actions

SDZ

CH1243598427

Produits pharmaceutiques

Temps réel estimé Cboe Europe
Autres places de cotation
 12:28:30 10/12/2024 		Varia. 5j. Varia. 1 janv.
37,80 CHF -0,34% Graphique intraday de Sandoz Group AG -2,95% +39,58%
03/12 Le CAC40 fait de la résistance Our Logo
03/12 Avis d'analystes du jour : Kering, Hermès, Michelin, UCB, Euroapi, Forvia, Galderma, Ipsen... Our Logo

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Federal Court Denies Motion To Add Infringement Counterclaim To Ustekinumab Impeachment Action
29/11
 AQ
Amgen Files BPCIA Complaint Against Accord Biopharma Regarding Denosumab Biosimilar
22/11
 AQ
BPCIA Lawsuit Against Accord's Proposed Prolia® / Xgeva® Biosimilar Filed By Amgen
21/11
 AQ
Is it Obvious? Sandoz v Bayer and a Patent's Inventive Step
15/11
 AQ
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
15/11
 GL
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
15/11
 AQ
FDA Accepts ABLAs For Prolia® / Xgeva® Biosimilars From Organon And Teva
07/11
 AQ
Sandoz reports third-quarter and nine-month 2024 sales
30/10
 GL
Sandoz reports third-quarter and nine-month 2024 sales
30/10
 AQ
Amgen Files BPCIA Complaint Against Fresenius Kabi Regarding Denosumab
16/10
 AQ
Amgen Files Fourth BPCIA Lawsuit Against Proposed Prolia® / Xgeva® Biosimilar – Fresenius Kabi's FKS518
15/10
 AQ
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
14/10
 AQ
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
11/10
 AQ
Myrbetriq® Patent Invalidated On Grounds Not Asserted By Any Party Violating Party Presentation Principle
04/10
 AQ
Federal Circuit Patent Watch: The Party Presentation Rule: Parties Map The Course Of Litigation, Not Judges
30/09
 AQ
Regeneron Files BPCIA Complaint Against Sandoz Regarding Aflibercept Biosimilar
05/09
 AQ
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi (Solriamfetol) Patent Litigation with Sandoz Inc
22/08
 AQ
FDA Approves Sandoz's ENVEEZU™ (Aflibercept-abzv)
15/08
 AQ
Amgen Files BPCIA Complaint Against Samsung Bioepsis Regarding Denosumab
15/08
 AQ
Sandoz receives FDA approval for Enzeevu, further strengthening US biosimilar position
13/08
 AQ
Introducing Jubbonti® and Wyost®, the first denosumab biosimilars on the Canadian market
12/08
 AQ
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
12/08
 GL
Sandoz reports second-quarter sales and half-year 2024 results
08/08
 GL
Sandoz reports second-quarter sales and half-year 2024 results
08/08
 AQ
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
25/07
 GL
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action SDZ
  4. Actualités Sandoz Group AG
  5. Communiqués
Etats-Unis

Zonebourse is also available in this country: United States.

Switch edition
Rester sur l'édition actuelle